COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,627 Articles (22,913 medRxiv, 8,714 bioRxiv)

Most recent first Previous |  Page 1013: Articles 10121-10130  | Next

Template-based design of peptides to inhibit SARS-CoV-2 RNA-dependent RNA polymerase complexation.
Chenna, A., Khan, W. H., Dash, R., Rathore, A. S., Goel, G.
10.1101/2022.01.24.477502 — Posted: 2022-01-25
Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail
Addetia, A., Park, Y.-J., Starr, T., Greaney, A. J., Sprouse, K., Bowen, J. E., Tiles, S. W., Van Voorhis, W. C., Bloom, J. D., Corti, D., Walls, A. C., Veesler, D.
10.1101/2022.01.21.477288 — Posted: 2022-01-25
Substantial immune response in Omicron infected breakthrough and unvaccinated individuals against SARS-CoV-2 variants of concerns
Yadav, P. D., Sapkal, G., Sahay, R. R., Potdar, V., Deshpande, G., Patil, D. Y., Nyayanit, D. A., Shete, A. M., Shastri, J., Awate, P., Malhotra, B., Abraham, P.
10.1101/2022.01.24.477043 — Posted: 2022-01-25
Close relatives of MERS-CoV in bats use ACE2 as their functional receptors
Yan, H., Wang, X., Xiong, Q., Cao, L., Ma, C., Liu, C., Si, J., Liu, P., Gu, M., Wang, C., Shi, L., Tong, F., Huang, M., Zhao, C., Li, J., Shen, C., Chen, Y., Zhao, H., Lan, K.
10.1101/2022.01.24.477490 — Posted: 2022-01-25 Discussion: Onsite
Mutations of SARS-CoV-2 variants of concern escaping Spike-specific T cells
Le Bert, N., Tan, A. T., Kunasegaran, K., Chia, A., Tan, N., Chen, Q., Hang, S. K., Qui, M. D., Chan, B. S., Low, J. G., Young, B., Ng, K. C., Chan, D. W. S., Lye, D. C. B., Bertoletti, A.
10.1101/2022.01.20.477163 — Posted: 2022-01-25
Design of immunogens for eliciting antibody responses that may protect against SARS-CoV-2 variants
Wang, E., Chakraborty, A. K.
10.1101/2022.01.24.477469 — Posted: 2022-01-25
The Choice of Response Alternatives in COVID-19 Social Science Surveys
Wright, D., Wolff, S. M., Jaspal, R., Barnett, J., Breakwell, G.
10.1101/2022.01.24.22269741 — Posted: 2022-01-25
Harringtonine has the effects of double blocking SARS-CoV-2 membrane fusion
Hu, S., Wang, N., Chen, S., Ding, Q., Wang, C., Ma, W., Zhang, X., Wu, Y., Lv, Y., Xue, Z., Bai, H., Ge, S., He, H., Lu, W., Zhang, T., Ding, Y., Liu, R., Han, S., Zhan, Y., Zhan, G., Guo, Z., Zhang, Y., Lu, J., Gao, J., Jia, Q., Wang, Y., Lu, S., Zhang, H., He, L.
10.1101/2022.01.22.477323 — Posted: 2022-01-25
BASELINE METABOLIC PROFILING AND RISK OF DEATH FROM COVID-19
Murata, G. H., Murata, A. E., Campbell, H. M., Mao, J. T.
10.1101/2022.01.22.22269691 — Posted: 2022-01-25
Learnings from the Australian First Few X Household Transmission Project for COVID-19
Marcato, A. J., Black, A. J., Walker, J., Meagher, N., Price, D. J., McVernon, J., The Australian FFX Household Transmission Project Group
10.1101/2022.01.23.22269031 — Posted: 2022-01-25

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).